MarketCapExport financials
10x Genomics (TXG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
10x Genomics Income Statement 2025-2011 | TXG
Brief overview of revenue and earnings at 10x Genomics
The conclusions below are based on five years of reported results. The revenue attributed to 10x Genomics moved from $299 million to $643 million between the two endpoints. The five-year change reached +115.1%, while CAGR stood at 16.6%. Revenue followed a strong upward trend without signs of stagnation.
Gross profit was $240 million at the start and $444 million at the end of the period (+84.7%). The relationship between sales and direct costs deteriorated. Gross profit as a share of revenue changed from 80.4% to 69.1%. The contraction points to pressure from direct costs or weaker pricing power.
The five-year EBITDA result moved by +95.2%: from −$520 million to −$24.8 million. The operating result developed less favorably than sales. EBITDA margin moved from −174% to −3.9%. The increased EBITDA share is a positive sign.
Across the five years, the net result shifted from −$543 million to −$43.5 million. The negative result improved without reaching break-even.
Market value was 18 billion dollars at the start and 2.6 billion dollars at the end. The market is not yet fully reflecting the fundamental progress.
Overall conclusion
Signs of deterioration dominate the five-year picture. The constructive conclusion rests on sales growth, an improving EBITDA margin and improving net profitability. Caution is warranted because of a low EBITDA margin, weaker gross profitability and lower investor confidence. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement 10x Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.64 B | 2.55 B | 5.64 B | 5.98 B | 8.99 B | 18 B | 3.66 B | - | 1.06 B | - | - | - | - | - | - |
Shares |
125 M | 120 M | 117 M | 114 M | 110 M | 101 M | 39.1 M | - | 82.9 M | - | - | - | - | - | - |
Historical Prices |
21.2 | 21.2 | 48.2 | 52.5 | 81.5 | 178 | 79.7 | - | - | - | - | - | - | - | - |
Net Income |
-43.5 M | -183 M | -255 M | -166 M | -58.2 M | -543 M | -31.3 M | -112 M | -18.8 M | - | - | - | - | - | - |
Revenue |
643 M | 611 M | 619 M | 516 M | 490 M | 299 M | 246 M | 146 M | 71.1 M | - | - | - | - | - | - |
Cost of Revenue |
199 M | 196 M | 209 M | 120 M | 74.1 M | 58.5 M | 61 M | 28.7 M | 10.6 M | - | - | - | - | - | - |
Gross Profit |
444 M | 414 M | 409 M | 396 M | 416 M | 240 M | 185 M | 118 M | 60.5 M | - | - | - | - | - | - |
Operating Income |
-61 M | -195 M | -265 M | -168 M | -52.3 M | -534 M | -30.6 M | -111 M | -18.4 M | - | - | - | - | - | - |
Interest Expense |
1.03 M | -2.07 M | -286 K | -198 K | 866 K | 1.68 M | 3.08 M | 2.41 M | 811 K | - | - | - | - | - | - |
EBITDA |
-24.8 M | -159 M | -230 M | -143 M | -31.1 M | -520 M | -23.5 M | -44.5 M | -14.1 M | - | - | - | - | - | - |
Operating Expenses |
505 M | 609 M | 675 M | 564 M | 469 M | 775 M | 215 M | 166 M | 78.9 M | - | - | - | - | - | - |
General and Administrative Expenses |
316 M | 344 M | 343 M | 298 M | 258 M | 202 M | 131 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement 10x Genomics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
128 M | 126 M | 124 M | 123 M | 121 M | 120 M | 119 M | 118 M | 117 M | 116 M | - | - | 114 M | 113 M | 113 M | 111 M | 110 M | 109 M | 108 M | 101 M | 99 M | 96.8 M | 96.2 M | 29.2 M | 15.6 M | 14.8 M | 14.5 M | 13.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-13.5 M | -27.5 M | 34.5 M | -34.4 M | -35.8 M | -37.9 M | -59.9 M | -93 M | -62.4 M | -50.7 M | - | - | -64.5 M | -42.4 M | - | -17.2 M | -11.1 M | -11.6 M | - | -65.8 M | -40.2 M | -21.1 M | -7.13 M | -9.6 M | -10.9 M | -3.64 M | -75.5 M | -15.3 M | -5.92 M | -15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
151 M | 149 M | 173 M | 155 M | 152 M | 153 M | 141 M | 154 M | 147 M | 134 M | - | - | 115 M | 114 M | - | 125 M | 116 M | 106 M | - | 71.8 M | 42.9 M | 71.9 M | 75.3 M | 61.2 M | 55.8 M | 53.6 M | 50.6 M | 36.6 M | 31.7 M | 27.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
44.7 M | 48.7 M | 47.8 M | 49.4 M | 45.3 M | 48.9 M | 48.1 M | 58.1 M | 47.2 M | 35.9 M | - | - | 27.7 M | 25.5 M | - | 24.5 M | 4.92 M | 17.1 M | - | 14.4 M | 10.1 M | 15.1 M | - | 15.5 M | 15 M | 14 M | - | 5.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
106 M | 100 M | 125 M | 105 M | 106 M | 104 M | 92.9 M | 95.5 M | 99.6 M | 98.4 M | - | - | 86.9 M | 89 M | - | 101 M | 111 M | 88.8 M | - | 57.4 M | 32.9 M | 56.8 M | 58.7 M | 45.7 M | 40.8 M | 39.6 M | 35.7 M | 31.4 M | 27.2 M | 23.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-17 M | -32.2 M | 30.1 M | -39.3 M | -41.5 M | -41.7 M | -61.5 M | -94.8 M | -63.4 M | -52 M | - | - | -63.1 M | -41.7 M | - | -15.9 M | -10.3 M | -10.2 M | - | -65.3 M | -39.4 M | -19.9 M | - | -9.1 M | -10.4 M | -3.04 M | - | -14.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-815 K | -1.16 M | 2.6 M | 2.14 M | 2.08 M | -56 K | 1 K | -1.25 M | -1.5 M | 19 K | - | - | 109 K | 128 K | - | 219 K | 209 K | 221 K | - | 397 K | 306 K | 662 K | - | 708 K | 695 K | 684 K | - | 659 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-7.09 M | -6.11 M | 46 M | -31.3 M | - | - | -52.3 M | - | - | -45.5 M | - | - | -50.4 M | -35.5 M | - | -15.9 M | -687 K | -5.46 M | - | -55.2 M | -32.9 M | -16.7 M | - | -4.88 M | -8.18 M | -2 M | - | -11.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
123 M | 133 M | 95 M | 145 M | 148 M | 146 M | 154 M | 190 M | 163 M | 150 M | - | - | 150 M | 131 M | - | 117 M | 121 M | 99 M | - | 123 M | 72.3 M | 76.7 M | - | 54.8 M | 51.2 M | 42.6 M | - | 46.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
66.4 M | 75.4 M | 74.4 M | 89.7 M | 81.7 M | 83 M | 85.8 M | 82.4 M | 91.5 M | 83.3 M | - | - | 79.3 M | 66.7 M | - | 62.1 M | 68.7 M | 56.9 M | - | 51.5 M | 44.4 M | 50.4 M | - | 32.6 M | 32.6 M | 26.9 M | - | 19.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company 10x Genomics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B |  USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.34 | -1.37 % | $ 173 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Veeva Systems
VEEV
|
$ 306.1 | -0.1 % | $ 50.1 B | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -5.76 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.94 | -5.99 % | $ 3.21 M |  China |
 |
HealthStream
HSTM
|
$ 28.69 | -0.14 % | $ 861 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
So-Young International
SY
|
$ 2.0 | 0.5 % | $ 156 M | China |
 |
American Well Corporation
AMWL
|
$ 12.0 | -3.73 % | $ 193 M | USA |
 |
Evolent Health
EVH
|
$ 4.79 | 1.7 % | $ 547 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.54 | -3.01 % | $ 1.26 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.46 | -3.31 % | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 103.68 | 1.53 % | $ 8.93 B | USA |
 |
Omnicell
OMCL
|
$ 35.87 | -3.96 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
$ 36.44 | 1.35 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 32.42 | -2.89 % | $ 2.38 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | -0.28 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 13.15 | 1.94 % | $ 786 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |